Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old

NCT02747927 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02747927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02747927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
April 26, 2016
Completion date
June 28, 2024
Enrollment
20,099 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers